Bio­gen ends agree­ment with Acor­da for mul­ti­ple scle­ro­sis drug Fampyra

Bio­gen is hand­ing back ex-US com­mer­cial­iza­tion rights to Acor­da Ther­a­peu­tics for the mul­ti­ple scle­ro­sis drug Fampyra.

Acor­da will have the drug in-house ef­fec­tive Jan. 1, 2025, now that Bio­gen has de­cid­ed to ter­mi­nate the li­cense and col­lab­o­ra­tion agree­ment be­tween the two com­pa­nies. The drug is mar­ket­ed as Fampyra (fam­pri­dine) in the EU as a treat­ment to im­prove the walk­ing of adults with mul­ti­ple scle­ro­sis and a walk­ing dis­abil­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER